Literature DB >> 8493358

Cecal ligation and puncture is associated with pulmonary injury in the rat: role of cyclooxygenase pathway products.

M J Schneidkraut1, R W Carlson.   

Abstract

The present studies evaluated the role cyclooxygenase products play in bacterial sepsis induced pulmonary injury in the rat. Lung injury was assessed by determining the pulmonary capillary filtration coefficient (Kf) and the lung lavage protein concentration four and 18 hours after cecal ligation and puncture. Four hours after cecal ligation, the Kf was unchanged from control, however, by 18 hours, the Kf was increased 171% (p < .05). Similarly, lung lavage protein levels were unchanged four hours after cecal ligation but were significantly (p < .05) elevated at 18 hours. On the other hand, pulmonary lavage immunoreactive thromboxane B2 (iTXB2) levels were increased both four and 18 hours after the initiation of sepsis. In order to determine if cyclooxygenase products played a role in the sepsis associated lung injury, ibuprofen was administered prior to cecal ligation. Ibuprofen pretreatment prevented the sepsis associated increase in both Kf and lung lavage protein concentration. These studies suggest that bacterial sepsis in the rat is associated with pulmonary injury and that early administration of ibuprofen ameliorates this damage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8493358     DOI: 10.1016/0090-6980(93)90110-s

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  2 in total

1.  Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice.

Authors:  C Stamme; D S Bundschuh; T Hartung; U Gebert; L Wollin; R Nüsing; A Wendel; S Uhlig
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

2.  Tezosentan reduces the microvascular filtration coefficient in isolated lungs from rats subjected to cecum ligation and puncture.

Authors:  Vladimir Kuklin; Mikhail Sovershaev; Thomas Andreasen; Vegard Skogen; Kirsti Ytrehus; Lars Bjertnaes
Journal:  Crit Care       Date:  2005-10-18       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.